RE:RE:RE:RE:RE:RE:hope "Question the science if no takers?"
This is why other pharmas are hanging in the balance to see if targetting the amyloid plaques really works. And so is PMN.
https://www.abc.net.au/news/health/2020-11-14/alzheimers-drug-aducanumab-faces-major-setback-with-fda/12881536
"To date, more than 300 Alzheimer's drug trials have failed, including more than 30 phase-3 clinical trials targeting amyloid plaques.
"There have been a number of antibody studies and they've all failed, and this is the one that's gotten the furthest," Professor Brodaty said. "It's a big blow."
The EMERGE trial, he said, had indicated some "signals of positive results", and that "we can't ignore the signals"."
G1945V